Savara Inc. (NASDAQ:SVRA) Stock Has Average Price Target of $10.25 According to Analysts

Savara Inc. (NASDAQ:SVRA) has received a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $10.25.

A number of research firms have recently commented on SVRA. Wall Street Zen downgraded Savara from a “hold” rating to a “sell” rating in a report on Sunday, October 4th. Royal Bank Of Canada set a $10.00 target price on Savara in a research report on Wednesday, October 7th. JPMorgan Chase & Co. initiated coverage on Savara in a report on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 target price on the stock. Citigroup reissued a “market outperform” rating on shares of Savara in a research report on Wednesday, October 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research report on Thursday, October 15th.

Institutional Trading of Savara

A number of institutional investors have recently modified their holdings of the company. Nan Fung Trinity HK Ltd. boosted its holdings in Savara by 1,088.3% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 1,842,350 shares of the company’s stock worth $9,507,000 after acquiring an additional 1,687,310 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in Savara in the third quarter worth about $54,000. Profund Advisors LLC increased its holdings in shares of Savara by 7.3% in the 3rd quarter. Profund Advisors LLC now owns 49,741 shares of the company’s stock valued at $257,000 after acquiring an additional 3,370 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Savara by 14.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 37,488 shares of the company’s stock worth $190,000 after purchasing an additional 4,874 shares during the period. Finally, Moody Aldrich Partners LLC raised its stake in Savara by 4.2% during the third quarter. Moody Aldrich Partners LLC now owns 502,932 shares of the company’s stock worth $2,595,000 after acquiring an additional 20,139 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Price Performance

Savara stock opened at $5.05 on Friday. Savara has a 1 year low of $3.94 and a 1 year high of $7.01. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.13 and a current ratio of 10.13. The firm has a 50 day moving average price of $4.98 and a 200 day moving average price of $5.36. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -8.71 and a beta of 0.32.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Sell-side analysts predict that Savara will post -0.66 earnings per share for the current year.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company’s work is centered on conditions with significant unmet medical needs, particularly diseases involving impaired lung function and abnormal accumulation of material in the lungs.

Savara’s lead product candidate is molgramostim, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is being developed for autoimmune pulmonary alveolar proteinosis, a rare lung disorder in which surfactant accumulates in the airspaces and interferes with breathing.